Statistiche di base
| CIK | 1783032 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Elevation Oncology, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-40523 Commission File Number ELEVATION ONCOLOGY, INC. (Exact name of registrant as specified in |
|
| July 23, 2025 |
CONTINGENT VALUE RIGHTS AGREEMENT Exhibit (d)(6) CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of July 23, 2025 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VI, Inc. |
|
| July 23, 2025 |
As filed with the Securities and Exchange Commission on July 23, 2025 As filed with the Securities and Exchange Commission on July 23, 2025 Registration No. |
|
| July 23, 2025 |
As filed with the Securities and Exchange Commission on July 23, 2025 As filed with the Securities and Exchange Commission on July 23, 2025 Registration No. |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 Elevation Oncology, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40523 84-1771427 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 23, 2025 |
As filed with the Securities and Exchange Commission on July 23, 2025 As filed with the Securities and Exchange Commission on July 23, 2025 Registration No. |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) ELEVATION ONCOLOGY, INC. (Name of Subject Company (Issuer)) CONCENTRA MERGER SUB VI, INC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Parent of Offeror)) |
|
| July 23, 2025 |
CERTIFICATE OF AMENDMENT RESTATED CERTIFICATE OF INCORPORATION ELEVATION ONCOLOGY, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ELEVATION ONCOLOGY, INC. Elevation Oncology, Inc. (hereinafter called the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. That the name of this Corporation is Elevation O |
|
| July 23, 2025 |
Exhibit 3.2 ELEVATION ONCOLOGY, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS As Amended and Restated on March 3, 2023 ELEVATION ONCOLOGY, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS TABLE OF CONTENTS Page Article I: STOCKHOLDERS 1 Section 1.1: Annual Meetings 1 Section 1.2: Special Meetings 1 Section 1.3: Notice of Meetings 1 Section 1.4: Adjournments 1 Section 1.5: Quor |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Elevation Oncology, Inc. (Name of Subject Company) Elevation Oncology, Inc. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28623U101 ( |
|
| July 23, 2025 |
As filed with the Securities and Exchange Commission on July 23, 2025 As filed with the Securities and Exchange Commission on July 23, 2025 Registration No. |
|
| July 23, 2025 |
As filed with the Securities and Exchange Commission on July 23, 2025 As filed with the Securities and Exchange Commission on July 23, 2025 Registration No. |
|
| July 23, 2025 |
As filed with the Securities and Exchange Commission on July 23, 2025 As filed with the Securities and Exchange Commission on July 23, 2025 Registration No. |
|
| July 23, 2025 |
As filed with the Securities and Exchange Commission on July 23, 2025 As filed with the Securities and Exchange Commission on July 23, 2025 Registration No. |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Elevation Oncology, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40523 84-1771427 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 23, 2025 |
MUTUAL NON-DISCLOSURE AGREEMENT Exhibit (d)(2) MUTUAL NON-DISCLOSURE AGREEMENT This Mutual Non-Disclosure Agreement (the “Agreement”) dated as of June 17, 2025 (the “Effective Date”) is by and between Elevation Oncology, Inc. |
|
| June 23, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Elevation Oncology, Inc. (Name of Subject Company) Elevation Oncology, Inc. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28623U101 |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ELEVATION ONCOLOGY, INC. (Name of Subject Company (Issuer)) CONCENTRA MERGER SUB VI, INC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Parent of Offeror)) TANG CAPITAL PART |
|
| June 23, 2025 |
Calculation of Filing Fee Tables SC TO-T Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Elevation Oncology, Inc. |
|
| June 23, 2025 |
Exhibit (a)(1)(B) [This space is intentionally left blank and reserved for registered shareholder detail] Letter of Transmittal To Tender Shares of Common Stock of ELEVATION ONCOLOGY, INC. |
|
| June 23, 2025 |
TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of ELEVATION ONCOLOGY, INC. |
|
| June 23, 2025 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ELEVATION ONCOLOGY, INC. |
|
| June 23, 2025 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of ELEVATION ONCOLOGY, INC. |
|
| June 23, 2025 |
Exhibit (e)(3) TENDER AND SUPPORT AGREEMENT This SUPPORT AGREEMENT (“Agreement”), dated as of , 2025, is made by and among Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), Concentra Merger Sub VI, Inc. |
|
| June 23, 2025 |
Exhibit (d)(3) Execution Version LIMITED GUARANTY This Limited Guaranty, dated as of June 8, 2025 (as may be amended, restated, supplemented or otherwise modified, this “Limited Guaranty”), by Tang Capital Partners, LP (the “Guarantor”), is made in favor of Elevation Oncology, Inc. |
|
| June 9, 2025 |
Exhibit 99.1 June 8, 2025 Joseph J. Ferra, Jr. [email protected] Re: Terms of Transition and Separation Dear Mr. Ferra: This letter confirms the agreement (“Agreement”) between you and Elevation Oncology, Inc. (the “Company”) concerning the terms of your separation and offers you the separation compensation below in exchange for a general release of claims, covenant not to sue and other |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Elevation Oncology, Inc. (Name of Subject Company) Elevation Oncology, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE (Title of Class of Securities) 28623U101 (CUSIP Number of C |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 Elevation Oncology, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40523 84-1771427 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 9, 2025 |
Exhibit 99.2 Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right Boston, Mass. June 9, 2025 – Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medi |
|
| June 9, 2025 |
FORM OF CONTINGENT VALUE RIGHTS AGREEMENT Exhibit 10.1 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [·] (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub VI, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Purchaser”), [·], as Rights Agent (as defined herei |
|
| June 9, 2025 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER DATED AS OF JUNE 8, 2025 AMONG CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB VI, INC. AND ELEVATION ONCOLOGY, INC. Table of Contents Page Article I DEFINITIONS 1 Section 1.01 Definitions 1 Section 1.02 Interpretation and Rules of Construction 12 Article II THE OFFER 13 Section 2.01 The Offer 13 Section 2.02 Company Actions 17 Article III THE MERGER 18 Se |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Elevation Oncology, Inc. |
|
| May 15, 2025 |
Separation Agreement dated March 31, 2025 by and between the Company and Valerie Malyvanh Jansen. Exhibit 10.1 Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. March 20, 2025 Valerie Malyvanh Jansen [****] Re: Terms of Transition and Separation Dear Dr. Jansen: This letter confirms the agreement (“Agreement”) between you and Elevation Oncology, Inc. (the “Comp |
|
| May 15, 2025 |
Exhibit 99.1 Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting - - Expects to file IND application for EO-1022 in 2026 - - Cash runway into 2H 2026 – Boston, Mass. May 15, 2025 – Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company foc |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025 Elevation Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40523 84-1771427 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 24, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 11, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 Elevation Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40523 84-1771427 (State or other jurisdiction of incorporation) (Commission |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Elevation Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40523 84-1771427 (State or other jurisdiction of incorporation) (Commission |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Elevation Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40523 84-1771427 (State or other jurisdiction of incorporation) (Commission |
|
| March 20, 2025 |
Exhibit 99.1 Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options - Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation - - Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigational New Drug (IND) application in |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 Elevation Oncology, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40523 84-1771427 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Elevation Oncology, Inc. |
|
| March 6, 2025 |
Exhibit 99.1 Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements - Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer - - Expect to report initial data from combination cohort |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-40523 ELEVATIO |
|
| March 6, 2025 |
Exhibit 19 Elevation Oncology, Inc. INSIDER TRADING POLICY (effective as of March 6, 2025) PURPOSE Elevation Oncology, Inc. (the “Company,” “we,” “us” or “our”) is committed to promoting high standards of honest and ethical business conduct and compliance with laws, rules and regulations. This Insider Trading Policy (the “Policy”), governing the purchase, sale and other dispositions of the Company |
|
| March 6, 2025 |
Exhibit 107.1 Calculation Of Filing Fee Tables Form S-8 Elevation Oncology, Inc. (Exact Name of Registrant as specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par value p |
|
| March 6, 2025 |
As filed with the Securities and Exchange Commission on March 6, 2025 As filed with the Securities and Exchange Commission on March 6, 2025 Registration No. |
|
| March 6, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Elevation Oncology, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization Elevation Oncology Securities Corporation Massachusetts |
|
| February 14, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with |
|
| February 5, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EX-1 2 jas.htm JOINT ACQUISITION STATEMENT EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addi |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 Elevation Oncology, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40523 84-1771427 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Elevation Oncology, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40523 84-1771427 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 14, 2024 |
ELEV / Elevation Oncology, Inc. / Logos Global Management LP Passive Investment SC 13G/A 1 elev13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Elevation Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 28623U101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga307422elev11142024.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value |
|
| November 14, 2024 |
ELEV / Elevation Oncology, Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| November 14, 2024 |
ELEV / Elevation Oncology, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ss4113337sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ELEVATION ONCOLOGY, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this State |
|
| November 12, 2024 |
SC 13G/A 1 ea0220923-13ga3aisling4elev.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) September 30, 2024 (Date of Event Whi |
|
| November 8, 2024 |
ELEV / Elevation Oncology, Inc. / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 elev13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Elevation Oncology, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 28623U101 (Cusip Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the approp |
|
| November 6, 2024 |
Exhibit 99.1 Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements - Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile - - Progressed into dose expansion portion of Phase 1 trial; additional monother |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Elevation Oncology, Inc. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| October 9, 2024 |
SC 13G/A 1 p24-2918sc13ga.htm ELEVATION ONCOLOGY, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 28623U101 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check th |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 Elevation Oncology, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40523 84-1771427 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 15, 2024 |
ELEV / Elevation Oncology, Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 8, 2024 |
ELEV / Elevation Oncology, Inc. / venBio Global Strategic Fund III, L.P. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) Antoinette Delhonte venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Address and |
|
| August 8, 2024 |
EX-99.7 3 ex99-7.htm Exhibit 99.7 SCHEDULE OF TRANSACTIONS The following table sets forth all transactions with respect to the shares of Common Stock effected during the past sixty days prior to the filing of this Amendment No. 4 to Schedule 13D by any Reporting Person. All of these transactions were effected in the open market through a broker. Name Date of Transaction Transaction Amount of Secur |
|
| August 8, 2024 |
EXHIBIT 99.6 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Antoinette Delhonte his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct o |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Elevation Oncology, Inc. |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| August 6, 2024 |
Form of Change in Control and Severance Agreement. Exhibit 10.1 Change in Control and Severance Agreement1 This Change in Control and Severance Agreement (the “Agreement”) is entered into by and between [Name] (the “Executive”) and Elevation Oncology, Inc., a Delaware corporation (the “Company”), effective as of [Date] (the “Effective Date”). 1.Qualifying Termination. If the Executive is subject to a Qualifying Termination, then, subject to Sectio |
|
| August 6, 2024 |
Exhibit 99.1 Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements - Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile - - Advancing into dose expansion portion of Phase 1 trial; additional mon |
|
| July 15, 2024 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| July 15, 2024 |
EX-99.A 2 d854392dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Elevation Oncology, Inc. Date: July 15, 2024 FRAZIER LIFE SCIENCES PUBLIC FUN |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Elevation Oncology, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40523 84-1771427 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2024 |
TABLE OF CONTENTS As Filed Pursuant to Rule 424(b)(3) Registration No. 333-279053 PROSPECTUS SUPPLEMENT (to Prospectus dated May 9, 2024) $75,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with TD Securities (USA) LLC, or TD Cowen, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement and the accompanying |
|
| May 7, 2024 |
ELEVATION ONCOLOGY, INC. 101 Federal Street., Suite 1900 Boston, MA 02110 May 7, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Jason Drory Re: Elevation Oncology, Inc. Registration Statement on Form S-3 (File No. 333-279053) filed May 2, 2024. Requested Date: May 9, 2024 Req |
|
| May 2, 2024 |
Exhibit 107 Calculation Of Filing Fee Tables Form S-3 (Form Type) Elevation Oncology, Inc. |
|
| May 2, 2024 |
Sales Agreement, dated May 2, 2024, by and between the Registrant and TD Securities (USA) LLC Exhibit 1.2 ELEVATION ONCOLOGY, INC. $75,000,000 COMMON STOCK SALES AGREEMENT May 2, 2024 TD Securities (USA) LLC (dba TD Cowen) 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Elevation Oncology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Place |
|
| May 2, 2024 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] ELEVATION ONCOLOGY, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MA |
|
| May 2, 2024 |
CERTAIN CONFIDENTAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ELEVATION ONCOLOGY, INC. |
|
| May 2, 2024 |
As filed with the Securities and Exchange Commission on May 2, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 2, 2024 Registration No. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 2, 2024 |
Exhibit 99.1 Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements - Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 - - Presented preclinical proof-of-concept data for HER3-ADC program at AACR Annual Meeting; on-tr |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Elevation Oncology, Inc. |
|
| May 2, 2024 |
Warrant to Purchase Common Stock, issued March 1, 2024, to K2 HealthVentures Equity Trust LLC. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ELEVATION ONCOLOGY, INC. |
|
| May 2, 2024 |
Exhibit 4.4 ELEVATION ONCOLOGY, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS Table of Contents Page ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2 OTHER DEFINITIONS 4 1.3 INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4 RULES OF CONSTRUCTION 5 ARTICLE 2 - THE SECURITIES 5 2.1 ISSUABLE IN SERIES 5 2.2 ESTABLISHMENT OF TERMS OF SERIES OF SECU |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| April 9, 2024 |
EX-99.A 2 d822741dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Elevation Oncology, Inc. Date: April 9, 2024 FRAZIER LIFE SCIENCES PUBLIC FUN |
|
| April 9, 2024 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 Elevation Oncology, Inc. |
|
| March 6, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation. Exhibit 97 Elevation Oncology, Inc. Compensation Recovery Policy (as adopted by the Board on September 29, 2023 and effective as of December 1, 2023) The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives certain incentive-based compensation in the event |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-40523 ELEVATIO |
|
| March 6, 2024 |
Exhibit 107.1 Calculation Of Filing Fee Tables Form S-8 Elevation Oncology, Inc. (Exact Name of Registrant as specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par value p |
|
| March 6, 2024 |
As filed with the Securities and Exchange Commission on March 6, 2024 As filed with the Securities and Exchange Commission on March 6, 2024 Registration No. |
|
| March 6, 2024 |
Exhibit 99.1 Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements -Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional data in 1H 2025 - - Preclinical proof-of-concept data for HER3-ADC program to be presented at AACR Annual M |
|
| March 6, 2024 |
Restated Certificate of Incorporation, as amended Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ELEVATION ONCOLOGY, INC. Elevation Oncology, Inc. (hereinafter called the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1.That the name of this Corporation is Elevation On |
|
| March 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 Elevation Oncology, Inc. |
|
| March 6, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Elevation Oncology, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization Elevation Oncology Securities Corporation Massachusetts |
|
| February 14, 2024 |
ELEV / Elevation Oncology, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 b111244sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check th |
|
| February 14, 2024 |
EX-99.A 2 ss3005723ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Statement on Schedule 13G, dated December 31, 2023 (this “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Elevation Oncology, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the S |
|
| February 14, 2024 |
ELEV / Elevation Oncology, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13G Passive Investment SC 13G 1 ss3005723sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ELEVATION ONCOLOGY, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 14, 2024 |
ELEV / Elevation Oncology, Inc. / K2 HealthVentures Equity Trust LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Elevation Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number |
|
| February 7, 2024 |
ELEV / Elevation Oncology, Inc. / ExodusPoint Capital Management, LP - SC 13G/A Passive Investment SC 13G/A 1 ef20020858sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Elevation Oncology, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement |
|
| February 7, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 ef20020858ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional j |
|
| February 6, 2024 |
SC 13G/A 1 ea192927-13ga2aisling4eleva.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2023 (Date of Event Whic |
|
| January 31, 2024 |
ELEV / Elevation Oncology, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ELEVATION ONCOLOGY, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 28623U101 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate th |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2024 Elevation Oncology, Inc. |
|
| January 22, 2024 |
ELEV / Elevation Oncology, Inc. / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Elevation Oncology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 28623U101 (CUSIP Number) January 10, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 22, 2024 |
ELEV / Elevation Oncology, Inc. / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 Elevation Oncology, Inc. |
|
| January 9, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 9, 2024 |
ELEV / Elevation Oncology, Inc. / Qiming U.S. Healthcare GP II, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Elevation Oncology, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 28623U101 (CUSIP Number) January 5, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 Elevation Oncology, Inc. |
|
| November 2, 2023 |
Employment Agreement dated July 12, 2023, by and between the Registrant and Joseph J. Ferra, Jr. Exhibit 10.1 July 12, 2023 VIA E-MAIL Joseph Ferra [email protected] Re: Executive Employment Agreement Dear Joe: On behalf of Elevation Oncology, Inc. (the “Company”), I am delighted to offer you the position of Chief Executive Officer of the Company. The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your employment with the Company in your new role. 1 |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| November 2, 2023 |
Employment Agreement dated July 12, 2023, by and between the Registrant and Tammy Furlong. Exhibit 10.2 July 12, 2023 VIA E-MAIL Tammy Furlong [email protected] Re: Executive Employment Agreement Dear Tammy: On behalf of Elevation Oncology, Inc. (the “Company”), I am delighted to offer you the position of Chief Financial Officer of the Company. The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your employment with the Company in your new ro |
|
| November 2, 2023 |
Exhibit 99.1 Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements - Enrollment is ongoing in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced solid tumors likely to express Claudin 18.2; preliminary safety and anti-tumor activity data expected in 1H 2025 - Boston, Mass. November 2, 2023 – Elevation Oncology, Inc. (Nasdaq |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Elevation Oncology, Inc. |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 Elevation Oncology, Inc. |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 Elevation Oncology, Inc. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Elevation Oncology, Inc. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| August 3, 2023 |
Exhibit 99.1 Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements ● Initial Phase 1 SYSA1801 (EO-3021) data presented by partner CSPC Pharmaceutical Group Limited at ASCO 2023 showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety pro |
|
| August 3, 2023 |
Certificate of Amendment of Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ELEVATION ONCOLOGY, INC. Elevation Oncology, Inc. (hereinafter called the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1.That the name of this Corporation is Elevation On |
|
| August 3, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265979 AMENDMENT NO. 1 DATED August 3, 2023 (To the Prospectus Dated August 4, 2022) $50,000,000 Common Stock This Amendment No. 1 to Prospectus (this “Amendment”) amends our prospectus dated August 4, 2022 (File No. 333-265979) (the “Prospectus”) relating to shares of our common stock that may be issued and sold in accordance |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2023 Elevation Oncology, Inc. |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Elevation Oncology, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40523 84-1771427 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 15, 2023 |
Exhibit 99.5 SCHEDULE OF TRANSACTIONS The following table sets forth all transactions with respect to the shares of Common Stock effected during the past sixty days prior to the filing of this Amendment No. 3 to Schedule 13D by any Reporting Person. All of these transactions were effected in the open market through a broker. Name Date of Transaction Transaction Amount of Securities Price Fund III |
|
| June 15, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Address and Tele |
|
| June 9, 2023 |
ELEV / Elevation Oncology Inc / ExodusPoint Capital Management, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Elevation Oncology Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) June 5, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| June 9, 2023 |
Form of Common Stock Purchase Warrant. Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ELEVATION ONCOLOGY, INC. Warrant Shares: [] Issue Date: June [13], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial |
|
| June 9, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn |
|
| June 9, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-265979 PROSPECTUS SUPPLEMENT (To Prospectus dated August 4, 2022) 17,810,000 Shares of Common Stock Pre-funded Warrants to Purchase 4,440,000 Shares of Common Stock Warrants to Purchase 22,250,000 Shares of Common Stock ELEVATION ONCOLOGY, INC. We are offering (i) 17,810,000 shares of our common stock and, in lieu of common |
|
| June 9, 2023 |
Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ELEVATION ONCOLOGY, INC. Warrant Shares: [] Issue Date: June [13], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the dat |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Elevation Oncology, Inc. |
|
| June 9, 2023 |
Underwriting Agreement dated June 8, 2023 Exhibit 1.1 Execution Version Elevation Oncology, Inc. (a Delaware corporation) 17,810,000 Shares of Common Stock Pre-funded Warrants to Purchase 4,440,000 Shares of Common Stock and Common Warrants to Purchase 22,250,000 Shares of Common Stock UNDERWRITING AGREEMENT June 8, 2023 SVB Securities LLC Cowen and Company, LLC as Representatives of the several Underwriters c/o SVB Securities LLC 53 Stat |
|
| June 8, 2023 |
ELEV / Elevation Oncology Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ELEVATION ONCOLOGY, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 28623U101 (CUSIP Number) JUNE 6, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whic |
|
| June 8, 2023 |
SUBJECT TO COMPLETION, DATED JUNE 8, 2023 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| June 5, 2023 |
Exhibit 99.2 Abstract #3016: First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting Claudin 18.2 in patients with resistant/refractory solid tumors Yakun Wang1, Jifang Gong1, Rongbo Lin2, Shen Zhao2, Jufeng Wang3, Qianli Wang3,Yan-qiao Zhang4, Dan Su4, Jingdong Zhang5, Qian Dong5, Ling Lin6, Wen Tian6, Ying Chen7, Yang Yang7, Xueyuan Zhang7, Xuechao Wa |
|
| June 5, 2023 |
Exhibit 99.1 Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation Oncology on track to initiate P |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2023 Elevation Oncology, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-40523 84-1771427 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 24, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) May 17, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| May 24, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn |
|
| May 15, 2023 |
Exhibit 99.1 Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements ● Partner CSPC Pharmaceutical Group Limited’s ongoing Phase 1 SYSA1801 (EO-3021) clinical trial data selected for poster presentation and poster discussion at ASCO 2023 ● Presented EO-3021 preclinical proof-of-concept data at AACR 2023 which demonstrated anti-tumor activity in m |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Elevation Oncology, Inc. |
|
| May 15, 2023 |
Separation Agreement, dated January 5, 2023, between the Company and Shawn M. Leland. Exhibit 10.1 Certain identified information has been excluded from this exhibit because such information both (i) is not material and (ii) would likely cause competitive harm if publicly disclosed. January 5, 2023 VIA E-MAIL Shawn M. Leland [email protected] Re: Terms of Separation. Dear Shawn: This letter confirms the agreement (“Agreement”) between you and Elevation Oncology, Inc. (t |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| April 27, 2023 |
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 27, 2023 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 17, 2023 |
Exhibit 99.1 Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023 EO-3021 demonstrated anti-tumor activity in preclinical models expressing varying levels of Claudin 18.2 EO-3021 induced a confirmed partial response in a patient with metastatic gastric cancer Company is on track to initiate a Phas |
|
| April 17, 2023 |
Exhibit 99.2 EO-3021: An antibody drug conjugate targeting CLDN18.2 expressing cancers David Dornan, PhD Elevation Oncology, Inc. Institution Logo, if desired Disclosure Information David Dornan I have the following relevant financial relationships to disclose: Employee of: Elevation Oncology, Inc. Consultant for: ReviR Therapeutics, Inc., Teon Therapeutics, Inc. Stockholder in: Elevation Oncology |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 Elevation Oncology, Inc. |
|
| April 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Elevation Oncology, Inc. |
|
| March 9, 2023 |
As filed with the Securities and Exchange Commission on March 9, 2023 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 9, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 The following table presents the name of significant subsidiaries of Elevation Oncology, Inc. and the location of jurisdiction or organization for such subsidiaries. Name: Jurisdiction/Organization Elevation Oncology Securities Corporation Massachusetts |
|
| March 9, 2023 |
Offer Letter dated March 16, 2022, by and between the Registrant and David Dornan. Exhibit 10.10 March 15, 2022 David Dornan, Ph.D. [****] [****] [****] Re: Employment Agreement Dear David: On behalf of Elevation Oncology, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your employment with the Company, should you accept our offer. 1.You will be employed to serve as t |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-40523 ELEVATIO |
|
| March 9, 2023 |
Elevation Oncology Reports Fourth Quarter and Full Year 2022 Financial Results Elevation Oncology Reports Fourth Quarter and Full Year 2022 Financial Results ● Remain on track to present EO-3021 preclinical proof-of-concept data in first half of 2023, and initiate Phase 1 clinical trial in the US in second half of 2023 ● Announced pipeline prioritization and realignment of resources focused on advancing EO-3021 ● Joseph Ferra, Chief Financial Officer, appointed Interim Chief Executive Officer ● Cash runway extended into the fourth quarter of 2024 NEW YORK, March 9, 2023 - Elevation Oncology, Inc. |
|
| March 9, 2023 |
Exhibit 107.1 Calculation Of Filing Fee Tables Form S-8 Elevation Oncology, Inc. (Exact Name of Registrant as specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.0001 par value |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Elevation Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40523 84-1771427 (State or other jurisdiction of incorporation) (Commission |
|
| March 3, 2023 |
Exhibit 3.1 ELEVATION ONCOLOGY, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS As Amended and Restated on March 3, 2023 elevation oncology, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS TABLE OF CONTENTS Page Article I: STOCKHOLDERS1 Section 1.1: Annual Meetings1 Section 1.2: Special Meetings1 Section 1.3: Notice of Meetings1 Section 1.4: Adjournments1 Section 1.5: Qu |
|
| February 24, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Elevation Oncology, Inc. and further agree to the filing of this agreement as an exhibit th |
|
| February 24, 2023 |
ELEV / Elevation Oncology Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
ELEV / Elevation Oncology, Inc. Common stock / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Elevation Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number |
|
| February 8, 2023 |
SC 13G/A 1 ea172925-13ga1aisling4eleva.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2022 (Date of Event Whic |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2023 Elevation Oncology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40523 84-1771427 (State or other jurisdiction of incorporation) (Commissio |
|
| November 3, 2022 |
Warrant to Purchase Common Stock, issued July 27, 2022, to K2 HealthVentures Equity Trust LLC. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ELEVATION ONCOLOGY, INC. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Elevation Oncology, Inc. |
|
| November 3, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ELEVATION ONCOLOGY, INC. |
|
| November 3, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ELEVATION ONCOLOGY, INC. |
|
| November 3, 2022 |
Exhibit 99.1 Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress ● On track to report additional interim seribantumab data from the Phase 2 CRESTONE study in the first half of 2023 ● Preparations are underway to initiate a Phase 1 clinical trial of EO-3021 in the US in 2023 NEW YORK, November 3, 2022 - Elevation Oncology, Inc. (Nasdaq: ELEV), a cl |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) July 27, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| September 26, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Address and Tele |
|
| September 26, 2022 |
Exhibit 99.4 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated: September 26, 2022 VENBIO |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2022 |
? Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress ? ? Presented initial seribantumab proof-of-concept data from Phase 2 CRESTONE study at ASCO 2022, including 33% response rate with two complete responses across all tumor types harboring NRG1 fusions ? ? Seribantumab granted Fast Track designation by FDA for tumor-agnostic treatment of solid tumors harboring NRG1 fusions ? ? Entered into an exclusive license agreement with CSPC Pharmaceutical Group to develop and commercialize EO-3021 (SYSA1801), a differentiated, clinical stage ADC targeting Claudin18. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Elevation Oncology, Inc. |
|
| August 4, 2022 |
Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-265979 PROSPECTUS $11,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus and the accompanying prospectus. In accordance with the terms of the Sales Agreemen |
|
| August 2, 2022 |
? ? August 2, 2022 ROB FREEDMANEMAIL: [email protected] DIRECT DIAL: +1 (650) 335-7292 ? ELEVATION ONCOLOGY, INC. 888 Seventh Ave., 12th Floor New York, NY 10106 ? August 2, 2022 ? VIA EDGAR ? United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.E. Washington, DC 20549 ? Attention: Margaret Schwartz Re: Elevation Onco |
|
| August 2, 2022 |
As filed with the Securities and Exchange Commission on August 2, 2022 ? As filed with the Securities and Exchange Commission on August 2, 2022 Registration No. |
|
| July 28, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 Elevation Oncology, Inc. |
|
| July 28, 2022 |
Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures Exhibit 99.2 ? ? Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures ? ? Initial tranche supports the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and execution of Company?s pipeline ? NEW YORK, JULY 28, 2022 - Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of |
|
| July 28, 2022 |
Exhibit 99.3 Expanding Pipeline with EO - 3021 Investor Conference Call JULY 28, 2022 Forward Looking Statements These slides contain forward - looking statements and information relating to Elevation Oncology, Inc. within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on f orw ard - look |
|
| July 28, 2022 |
Exhibit 99.1 ? Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group ? ? Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801) ? Expands pipeline to now include two clinical stage precision oncology candidates for patients w |
|
| July 11, 2022 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Elevation Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28623U101 (CUSIP Number) June 08, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| July 1, 2022 |
Exhibit 107 Calculation Of Filing Fee Tables ? Form S-3 (Form Type) ? Elevation Oncology, Inc. |
|
| July 1, 2022 |
Sales Agreement, dated July 1, 2022, by and between the Registrant and Cowen and Company LLC Exhibit 1.2 ? ELEVATION ONCOLOGY, INC. $50,000,000 ? COMMON STOCK ? SALES AGREEMENT ? July 1, 2022 ? Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 ? Ladies and Gentlemen: ? Elevation Oncology, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1.Issuance and Sale of Placement Shares. The Compan |
|
| July 1, 2022 |
? Exhibit 4.4 ELEVATION ONCOLOGY, INC. And , as Trustee INDENTURE Dated as of , ? ? ? TABLE OF CONTENTS Table of Contents Page ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS. 1 1.2 OTHER DEFINITIONS. 4 1.3 INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 4 1.4 RULES OF CONSTRUCTION. 5 ARTICLE 2 - THE SECURITIES 5 2.1 ISSUABLE IN SERIES. 5 2.2 ESTABLISHMENT OF TERMS OF S |
|
| July 1, 2022 |
? Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] ELEVATION ONCOLOGY, INC. [If applicable, insert?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO |
|
| July 1, 2022 |
As filed with the Securities and Exchange Commission on July 1, 2022 Registration No. |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 Elevation Oncology, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-40523 81-1771427 (State or other jurisdiction of incorporation) (Commi |
|
| June 10, 2022 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Elevation Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28623U101 (CUSIP Number) May 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| May 27, 2022 |
Exhibit 99.2 Initial CRESTONE Data Investor Conference Call MAY 26, 2022 Forward Looking Statements These slides contain forward - looking statements and information relating to Elevation Oncology, Inc. within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on forward - looki ng statements |
|
| May 27, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Address and Tele |
|
| May 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Elevation Oncology, Inc. |
|
| May 27, 2022 |
Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022 ? ? Positive initial data support the potential of seribantumab to induce deep and durable benefit for patients with tumors harboring NRG1 fusions ? ? Clinical activity observed includes a 33% response rate with 2 complete responses across all tumor types harboring NRG1 fusions, and a 36% response rate in patients with NSCLC; ongoing durations of response range from 1. |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Elevation Oncology, Inc. |
|
| May 5, 2022 |
Elevation Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress ? ? Initial seribantumab clinical data from Phase 2 CRESTONE study selected for oral presentation at ASCO 2022 ? ? David Dornan, PhD appointed Chief Scientific Officer, bringing deep oncology R&D and drug development expertise to further Company?s continued focus on future pipeline expansion throughout 2022 and beyond ? ? Cash, cash equivalents and marketable securities totaling $132. |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as per |
|
| April 29, 2022 |
DEF 14A 1 tmb-20220617xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Conf |
|
| March 3, 2022 |
Exhibit 21.1 The following table presents the name of significant subsidiaries of Elevation Oncology, Inc. and the location of jurisdiction or organization for such subsidiaries. Name: Jurisdiction/Organization Elevation Oncology Securities Corporation Massachusetts ? |
|
| March 3, 2022 |
As filed with the Securities and Exchange Commission on March 3, 2022 As filed with the Securities and Exchange Commission on March 3, 2022 Registration No. |
|
| March 3, 2022 |
?Exhibit 107.1 Calculation Of Filing Fee Tables Form S-8 Elevation Oncology, Inc. (Exact Name of Registrant as specified in its Charter) ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.000 |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 3, 2022 |
Elevation Oncology Reports Fourth Quarter and Full Year 2021 Financial Results Elevation Oncology Reports Fourth Quarter and Full Year 2021 Financial Results ? ? On track to present initial clinical data from Cohort 1 of the Phase 2 CRESTONE study in mid-2022 ? ? Continued focus on strategy for seribantumab program and future pipeline expansion throughout 2022 NEW YORK, March 3, 2022 - Elevation Oncology, Inc. |
|
| March 3, 2022 |
Exhibit 10.11 February 2, 2021 Valerie Malyvanh Jansen, MD, PhD 149 Burberry Glen Blvd Nolensville, TN 37135 Re: Executive Employment Agreement Dear Valerie: On behalf of Elevation Oncology, Inc. (the ?Company?), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the ?Agreement?) is to set forth the terms of your employment with the Company, should you acc |
|
| March 3, 2022 |
Exhibit 4.2 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Elevation Oncology, Inc. (?we,? ?us? or ?our?) had common stock, $0.0001 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended, and listed on The Nasdaq Global Select Market under the trading symbol ?ELEV. |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 Elevation Oncology, Inc. |
|
| February 14, 2022 |
ELEV / Elevation Oncology, Inc. Common stock / Boxer Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 14, 2022 |
ELEV / Elevation Oncology, Inc. Common stock / Aisling Capital IV, LP - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the Appropriate Box to Desig |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Elevation Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2022 with respect to the shares of common stock, par value $0.0001 per share, of Elevation Oncology, Inc. and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provi |
|
| February 14, 2022 |
EXHIBIT A JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0. |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Elevation Oncology, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 28623U101 (CUSIP Number) June 29, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 21, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 Elevation Oncology, Inc. |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| November 12, 2021 |
Exhibit 99.1 ? Elevation Oncology Reports Third Quarter 2021 Financial Results ? ? Global Expansion of the Phase 2 CRESTONE Study into Canada and Australia ? Case Study of a Patient with Pancreatic Cancer Harboring an NRG1 Fusion and Treated with Seribantumab Under Compassionate Use Highlighted a Confirmed Partial Response and Durable Clinical Benefit ? Strengthened Management Team with the Promot |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Elevation Oncology, Inc. |
|
| August 12, 2021 |
Exhibit 3.2 ? ELEVATION ONCOLOGY, INC. (a Delaware corporation) ? RESTATED BYLAWS ? As Adopted June 4, 2021 and As Effective June 29, 2021 ? ? ? ? ELEVATION ONCOLOGY, INC. (a Delaware corporation) RESTATED BYLAWS TABLE OF CONTENTS ? ? ? ? ? ? Page ? ? ? Article I: STOCKHOLDERS 1 ? ? ? Section 1.1: Annual Meetings 1 Section 1.2: Special Meetings 1 Section 1.3: Notice of Meetings 1 Section 1.4: Adjo |
|
| August 12, 2021 |
Restated Certificate of Incorporation Exhibit 3.1 ELEVATION ONCOLOGY, INC. RESTATED CERTIFICATE OF INCORPORATION Elevation Oncology, Inc., a Delaware corporation, hereby certifies as follows: 1.The name of this corporation is ?Elevation Oncology, Inc.? The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was April 29, 2019 under the name 14ner Oncology, Inc. 2.The Res |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Elevation Oncology, Inc. |
|
| August 12, 2021 |
Exhibit 99.1 ? Elevation Oncology Reports Second Quarter 2021 Financial Results -Entered into collaboration with Caris Life Sciences for the identification of oncogenic fusions and driver alterations - -Raised over $100 million in IPO gross proceeds, extending cash runway into Q2 2023 - -Strengthened corporate leadership with key appointments to the management team and Board of Directors - ? NEW Y |
|
| August 6, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 Elevation Oncology, Inc. |
|
| August 6, 2021 |
Change in Control and Severance Agreement Exhibit 99.1 Change in Control and Severance Agreement This Change in Control and Severance Agreement (the ?Agreement?) is entered into by and between [Name] (the ?Executive?) and Elevation Oncology, Inc., a Delaware corporation (the ?Company?), effective as of (the ?Effective Date?). 1.Qualifying Termination. If the Executive is subject to a Qualifying Termination, then, subject to Sections 3, 8, |
|
| July 9, 2021 |
ELEV / Elevation Oncology, Inc. Common stock / Boxer Capital, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) June 29, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| July 9, 2021 |
EX-99.2 3 efc21-446ex99-2.htm Exhibit 99.2 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints David Pezeshki his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in h |
|
| July 9, 2021 |
Joint Filing Agreement, dated July 9, 2021, among the Reporting Persons. EX-99.1 2 d201353dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the common stock of Elevation Oncology, Inc., par value $0.0001 per share, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Se |
|
| July 9, 2021 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of July 9, 2021, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Asset Management, LP and Bihua C |
|
| July 9, 2021 |
ELEV / Elevation Oncology, Inc. Common stock / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Elevation Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28623U101 (CUSIP Number) June 29, 2021? (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| July 9, 2021 |
EX-99.1 2 efc21-446ex99-1.htm Exhibit 99.1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Da |
|
| July 9, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Elevation Oncology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28623U101 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Address and Telephone |
|
| June 25, 2021 |
As filed with the Securities and Exchange Commission on June 24, 2021 As filed with the Securities and Exchange Commission on June 24, 2021 Registration No. |
|
| June 25, 2021 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(1) ?Registration No. 333-256787? Prospectus 6,250,000 shares Common stock This is an initial public offering of shares of common stock by Elevation Oncology, Inc. We are offering 6,250,000 shares of our common stock to be sold in the offering. The initial public offering price is $16.00 per share. Prior to this offering, there has been no public mar |
|
| June 24, 2021 |
June 24, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Deanna Virginio Re: Elevation Oncology, Inc. Registration Statement on Form S-1 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that as of t |
|
| June 24, 2021 |
Elevation Oncology, Inc. 888 Seventh Avenue, 12th Floor New York, NY 10106 June 24, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Christopher Edwards Deanna Virginio Gary Newberry Kevin Kuhar Re: Elevation Oncology, Inc. Registration Statement on Form S-1 (File No. 333-256787) originally filed June 4 |
